Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
| Treament | Trials | |||||
|---|---|---|---|---|---|---|
| clinical deterioration | clinical improvement | deaths | viral clearance | |||
| Immunosuppressants drugs | 1.11 [0.59; 2.09], 1 RCT, I2=0% inconclusive result | 1.06 [0.80; 1.41], 1 RCT, I2=0% inconclusive result | 0.87 [0.78; 0.99], 3 RCTs, I2=0% demonstrated moderate degree of certainty | - | ||
| Immunostimulants drugs | - | - | 2.00 [0.16; 24.66], 1 RCT, I2=0% inconclusive result | - | ||
| leflunomide | - | - | - | - | ||
| anti-inflammatory therapies | 0 | - | - | - | - | |
| Apilimod | 0 | - | - | - | - | |
| corticosteroids | 0 | - | - | - | - | |
| inhaled corticosteroids | 0 | - | - | - | - | |
| Kinase inhibitors | 0 | - | - | - | - | |
| meplazumab | 0 | - | - | - | - | |
| pirfenidone | 0 | - | - | - | - | |
| Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
| sargramostim | 0 | - | - | - | - | |
| statins | 0 | - | - | - | - | |
| thymosin | 0 | - | - | - | - | |